Peptide treatment of human plasma disrupts metabolic and age-related pathologies via heat shock protein 70

Abstract

Aim: A seven amino acid cyclic peptide has been applied to human blood plasma treated with glucose metabolite methylglyoxal (MG) in “proof of concept” experiments to determine the peptide’s ability to counteract pathologies associated with hyperglycemia. Similar pathologies are evident during aging and in age-related disorders. In fact, elevated MG levels in the blood lead directly to diabetic complications and accelerated aging, including cognitive decline. These changes are attributed to oxidant stress and amyloidogenesis, the latter involving toxic accumulations of blood and tissue proteins.

Methods: cSKE7 was redesigned from cell survival-promoting and anti-inflammatory fragments near the N-terminus of human/primate “orphan” protein DSEP/Dermcidin and incubated at low micromolar concentrations with the MG-stressed human plasma for 24 hours. The modified design of the new compound offers several practical advantages over predecessors including cyclic stability and a marked increase in aqueous solubility.

Results: The peptide dispersed thioflavin-T-stained amyloid aggregates and reduced oxidant stress as measured by plasma levels of free thiols and of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity. Since these N-terminal fragments of DSEP/Dermcidin have been shown to bind and influence the activity of heat shock protein 70 (HSP70), HSP70 inhibitor pifithrin-μ was added to the plasma prior to peptide treatment. The inhibitor disrupted amyloid dispersion and both peptide-induced and, in some cases, normally occurring antioxidant effects, suggesting these reparative activities are HSP70 dependent.

Conclusions: The results are discussed in terms of their potential use in new therapies for the complications of metabolic disease and disorders of aging that result from a deterioration of the quality control mechanisms of proteostasis.

Keywords

peptide / methylglyoxal / heat shock protein 70 / metabolic disease / protein aggregate disease

References

[1] Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021; 289: 268-92.

[2] Gafni J, Sohar E, Heller H. The inherited amyloidoses: their clinical and theoretical significance. Lancet. 1964; 283: 71—4.

[3] Symmers WS. Primary amyloidosis: a review. J Clin Pathol. 1956; 9: 187-211.

[4] Njemini R, Bautmans I, Onyema OO, Van Puyvelde K, Demanet C, Mets T. Circulating heat shock protein 70 in health, aging and disease. BMC Immunol. 2011; 12: 24.

[5] Li D, Liang S, Wen J, Tang J, Deng S, Liu Y. Extracellular HSPs: The Potential Target for Human Disease Therapy. Molecules. 2022; 27: 2361.

[6] Qu B, Jia Y, Liu Y, Wang H, Ren G, Wang H. The detection and role of heat shock protein 70 in various nondisease conditions and disease conditions: a literature review. Cell Stress Chaperones. 2015; 20: 885-92.

[7] Bennici G, Almahasheer H, Alghrably M, Valensin D, Kola A, Kokotidou C, et al. Mitigating diabetes associated with reactive oxygen species (ROS) and protein aggregation through pharmacological interventions. RSC Adv. 2024; 14: 17448-60.

[8] Mulyani WRW, Sanjiwani MID, Sandra, Prabawa IPY, Lestari AAW, Wihandani DM, et al. Chaperone—Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2020; 13: 559-68.

[9] Mukherjee A, Morales—Scheihing D, Butler PC, Soto C. Type 2 diabetes as a protein misfolding disease. Trends Mol Med. 2015; 21: 439-49.

[10] Esmaeilzadeh A, Mohammadi V, Elahi R, Rezakhani N. The role of heat shock proteins (HSPs) in type 2 diabetes mellitus pathophysiology. J Diabetes Complications. 2023; 37: 108564.

[11] Bellini S, Barutta F, Mastrocola R, Imperatore L, Bruno G, Gruden G. Heat Shock Proteins in Vascular Diabetic Complications: Review and Future Perspective. Int J Mol Sci. 2017; 18: 2709.

[12] Domingueti CP, Dusse LM, Carvalho Md, de Sousa LP, Gomes KB, Fernandes AP. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications. 2016; 30: 738—45.

[13] Sirangelo I, Iannuzzi C. Understanding the Role of Protein Glycation in the Amyloid Aggregation Process. Int J Mol Sci. 2021; 22: 6609.

[14] Iannuzzi C, Irace G, Sirangelo I. Differential effects of glycation on protein aggregation and amyloid formation. Front Mol Biosci. 2014; 1: 9.

[15] Meakin PJ, Coull BM, Tuharska Z, McCaffery C, Akoumianakis I, Antoniades C, et al. Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction. J Clin Invest. 2020; 130: 4104—17.

[16] Díez R, Madero M, Gamba G, Soriano J, Soto V. Renal AA Amyloidosis in Patients with Type 2 Diabetes Mellitus. Nephron Extra. 2014; 4: 119—26.

[17] Sack GH Jr. Serum amyloid A — a review. Mol Med. 2018; 24: 46.

[18] Ding L, Hou Y, Liu J, Wang X, Wang Z, Ding W, et al. Circulating Concentrations of advanced Glycation end Products, Carboxymethyl Lysine and Methylglyoxal are Associated With Renal Function in Individuals With Diabetes. J Ren Nutr. 2024; 34: 154-60.

[19] Asiri MMH, Engelsman S, Eijkelkamp N, Höppener JWM. Amyloid Proteins and Peripheral Neuropathy. Cells. 2020; 9: 1553.

[20] Beeri MS, Moshier E, Schmeidler J, Godbold J, Uribarri J, Reddy S, et al. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev. 2011; 132: 583-7.

[21] Zhang Y, Zhang Z, Tu C, Chen X, He R. Advanced Glycation End Products in Disease Development and Potential Interventions. Antioxidants (Basel). 2025; 14: 492.

[22] Desai KM, Chang T, Wang H, Banigesh A, Dhar A, Liu J, et al. Oxidative stress and aging: is methylglyoxal the hidden enemy? Can J Physiol Pharmacol. 2010; 88: 273-84.

[23] Schalkwijk CG, Micali LR, Wouters K. Advanced glycation endproducts in diabetes—related macrovascular complications: focus on methylglyoxal. Trends Endocrinol Metab. 2023; 34: 49-60.

[24] Schalkwijk CG, Stehouwer CDA. Methylglyoxal, a Highly Reactive Dicarbonyl Compound, in Diabetes, Its Vascular Complications, and Other Age—Related Diseases. Physiol Rev. 2020; 100: 407-61.

[25] Bouma B, Kroon—Batenburg LM, Wu YP, Brünjes B, Posthuma G, Kranenburg O, et al. Glycation induces formation of amyloid cross—beta structure in albumin. J Biol Chem. 2003; 278: 41810—9.

[26] Uceda AB, Mariño L, Casasnovas R, Adrover M. An overview on glycation: molecular mechanisms, impact on proteins, pathogenesis, and inhibition. Biophys Rev. 2024; 16: 189-218.

[27] Rabbani N. Methylglyoxal and glyoxalase 1—a metabolic stress pathway—linking hyperglycemia to the unfolded protein response and vascular complications of diabetes. Clin Sci (Lond). 2022; 136: 819—24.

[28] Chen Y, Meng Z, Li Y, Liu S, Hu P, Luo E. Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications. Mol Med. 2024; 30: 141.

[29] Lubkowska A, Dudzińska W, Pluta W. Antioxidant Enzyme Activity and Serum HSP70 Concentrations in Relation to Insulin Resistance and Lipid Profile in Lean and Overweight Young Men. Antioxidants (Basel). 2023; 12: 655.

[30] Hooper PL, Hooper JJ. Loss of defense against stress: diabetes and heat shock proteins. Diabetes Technol Ther. 2005; 7: 204-8.

[31] Khandia R, Munjal AK, Iqbal HMN, Dhama K. Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders. Recent Pat Inflamm Allergy Drug Discov. 2017; 10: 94-104.

[32] Gomez CR. Role of heat shock proteins in aging and chronic inflammatory diseases. Geroscience. 2021; 43: 2515—32.

[33] Cunningham TJ, Hodge L, Speicher D, Reim D, Tyler—Polsz C, Levitt P, et al. Identification of a survival—promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin. J Neurosci. 1998; 18: 7047-60.

[34] Schittek B. The multiple facets of dermcidin in cell survival and host defense. J Innate Immun. 2012; 4: 349-60.

[35] Cunningham TJ, Jing H, Akerblom I, Morgan R, Fisher TS, Neveu M. Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells. Exp Neurol. 2002; 177: 32-9.

[36] Cunningham TJ, Greenstein JI, Loewenstern J, Degermentzidis E, Yao L. Anti—inflammatory peptide regulates the supply of heat shock protein 70 monomers: implications for aging and age—related disease. Rejuvenation Res. 2015; 18: 136-44.

[37] Cunningham TJ, Maciejewski J, Yao L. Inhibition of secreted phospholipase A2 by neuron survival and anti—inflammatory peptide CHEC—9. J Neuroinflammation. 2006; 3: 25.

[38] Cunningham TJ, Yao L, Oetinger M, Cort L, Blankenhorn EP, Greenstein JI. Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroinflammation. 2006; 3: 26.

[39] Cunningham TJ, Souayah N, Jameson B, Mitchell J, Yao L. Systemic treatment of cerebral cortex lesions in rats with a new secreted phospholipase A2 inhibitor. J Neurotrauma. 2004; 21: 1683—91.

[40] Stocki P, Wang XN, Morris NJ, Dickinson AM. HSP70 natively and specifically associates with an N—terminal dermcidin—derived peptide that contains an HLA—A*03 antigenic epitope. J Biol Chem. 2011; 286: 12803—11.

[41] Cunningham TJ, Greenstein J, Yao L, Fischer I, Connors T. Heptamer Peptide Disassembles Native Amyloid in Human Plasma Through Heat Shock Protein 70. Rejuvenation Res. 2018; 21: 527-34.

[42] Srikanth V, Westcott B, Forbes J, Phan TG, Beare R, Venn A, et al. Methylglyoxal, cognitive function and cerebral atrophy in older people. J Gerontol A Biol Sci Med Sci. 2013; 68: 68-73.

[43] Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol. 2019; 20: 421—35.

[44] Cuervo AM, Dice JF. Age—related decline in chaperone—mediated autophagy. J Biol Chem. 2000; 275: 31505—13.

[45] Choi JS, Joo SH. Recent Trends in Cyclic Peptides as Therapeutic Agents and Biochemical Tools. Biomol Ther (Seoul). 2020; 28: 18-24.

[46] Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012; 2012: 195727.

[47] Qing R, Hao S, Smorodina E, Jin D, Zalevsky A, Zhang S. Protein Design: From the Aspect of Water Solubility and Stability. Chem Rev. 2022; 122: 14085-179.

[48] Thakur R, Suri CR, Kaur IP, Rishi P. Peptides as Diagnostic, Therapeutic, and Theranostic Tools: Progress and Future Challenges. Crit Rev Ther Drug Carrier Syst. 2022; 40: 49-100.

[49] Halvey P, Farutin V, Koppes L, Gunay NS, Pappas DA, Manning AM, et al. Variable blood processing procedures contribute to plasma proteomic variability. Clin Proteomics. 2021; 18: 5.

[50] Hassis ME, Niles RK, Braten MN, Albertolle ME, Ewa Witkowska H, Hubel CA, et al. Evaluating the effects of preanalytical variables on the stability of the human plasma proteome. Anal Biochem. 2015; 478: 14-22.

[51] Shen Q, Björkesten J, Galli J, Ekman D, Broberg J, Nordberg N, et al. Strong impact on plasma protein profiles by precentrifugation delay but not by repeated freeze—thaw cycles, as analyzed using multiplex proximity extension assays. Clin Chem Lab Med. 2018; 56: 582-94.

[52] Do HT, Franke P, Volpert S, Klinksiek M, Thome M, Held C. Measurement and modelling solubility of amino acids and peptides in aqueous 2—propanol solutions. Phys Chem Chem Phys. 2021; 23: 10852-63.

[53] Johnson RN, Metcalf PA, Baker JR. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta. 1983; 127: 87-95.

[54] Mok YF, Ryan TM, Yang S, Hatters DM, Howlett GJ, Griffin MD. Sedimentation velocity analysis of amyloid oligomers and fibrils using fluorescence detection. Methods. 2011; 54: 67-75.

[55] Xue C, Lin TY, Chang D, Guo Z. Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R Soc Open Sci. 2017; 4: 160696.

[56] Kunjithapatham R, Geschwind JF, Devine L, Boronina TN, O’Meally RN, Cole RN, et al. Occurrence of a multimeric high—molecular—weight glyceraldehyde—3—phosphate dehydrogenase in human serum. J Proteome Res. 2015; 14: 1645-56.

[57] Twarda—Clapa A, Olczak A, Białkowska AM, Koziołkiewicz M. Advanced Glycation End—Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells. 2022; 11: 1312.

[58] Semchyshyn H. Fructose—mediated AGE—RAGE axis: approaches for mild modulation. Front Nutr. 2024; 11: 1500375.

[59] Gade Malmos K, Blancas—Mejia LM, Weber B, Buchner J, Ramirez—Alvarado M, Naiki H, et al. ThT 101: a primer on the use of thioflavin T to investigate amyloid formation. Amyloid. 2017; 24: 1-16.

[60] Oliveira PVS, Laurindo FRM. Implications of plasma thiol redox in disease. Clin Sci (Lond). 2018; 132: 1257—80.

[61] Fu X, Cate SA, Dominguez M, Osborn W, Özpolat T, Konkle BA, et al. Cysteine Disulfides (Cys—ss—X) as Sensitive Plasma Biomarkers of Oxidative Stress. Sci Rep. 2019; 9: 115.

[62] Kleinman WA, Richie JP Jr. Status of glutathione and other thiols and disulfides in human plasma. Biochem Pharmacol. 2000; 60: 19-29.

[63] Guo S, Wharton W, Moseley P, Shi H. Heat shock protein 70 regulates cellular redox status by modulating glutathione—related enzyme activities. Cell Stress Chaperones. 2007; 12: 245-54.

[64] Lee HJ, Howell SK, Sanford RJ, Beisswenger PJ. Methylglyoxal can modify GAPDH activity and structure. Ann N Y Acad Sci. 2005; 1043: 135—45.

[65] Tossounian MA, Zhang B, Gout I. The Writers, Readers, and Erasers in Redox Regulation of GAPDH. Antioxidants (Basel). 2020; 9: 1288.

[66] Treaster SB, Chaudhuri AR, Austad SN. Longevity and GAPDH Stability in Bivalves and Mammals: A Convenient Marker for Comparative Gerontology and Proteostasis. PLoS One. 2015; 10: e0143680.

[67] Vigelsø A, Dybboe R, Hansen CN, Dela F, Helge JW, Guadalupe Grau A. GAPDH and β—actin protein decreases with aging, making Stain—Free technology a superior loading control in Western blotting of human skeletal muscle. J Appl Physiol (1985). 2015; 118: 386-94.

[68] Nicholls C, Li H, Liu J. GAPDH: a common enzyme with uncommon functions. Clin Exp Pharmacol Physiol. 2012; 39: 674—9.

[69] Vangrieken P, Scheijen JLJM, Schiffers PMH, van de Waarenburg MPH, Foulquier S, Schalkwijk CCG. Modelling the effects of elevated methylglyoxal levels on vascular and metabolic complications. Sci Rep. 2025; 15: 6025.

[70] Ahmed A, Shamsi A, Khan MS, Husain FM, Bano B. Methylglyoxal induced glycation and aggregation of human serum albumin: Biochemical and biophysical approach. Int J Biol Macromol. 2018; 113: 269-76.

[71] Barinova KV, Serebryakova MV, Melnikova AK, Medvedeva MV, Muronetz VI, Schmalhausen EV. Mechanism of inactivation of glyceraldehyde—3—phosphate dehydrogenase in the presence of methylglyoxal. Arch Biochem Biophys. 2023; 733: 109485.

[72] Naftaly A, Izgilov R, Omari E, Benayahu D. Revealing Advanced Glycation End Products Associated Structural Changes in Serum Albumin. ACS Biomater Sci Eng. 2021; 7: 3179-89.

[73] Seidler NW, Kowalewski C. Methylglyoxal—induced glycation affects protein topography. Arch Biochem Biophys. 2003; 410: 149-54.

[74] Kalapos MP. Where does plasma methylglyoxal originate from? Diabetes Res Clin Pract. 2013; 99: 260-71.

[75] Han Y, Randell E, Vasdev S, Gill V, Gadag V, Newhook LA, et al. Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication—free patients with Type 1 diabetes. Mol Cell Biochem. 2007; 305: 123-31.

[76] Boye KS, Thieu VT, Lage MJ, Miller H, Paczkowski R. The Association Between Sustained HbA1c Control and Long—Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study. Adv Ther. 2022; 39: 2208-21.

[77] Sun D, van Greevenbroek MMJ, Scheijen JLJM, Kelly J, Schalkwijk CG, Wouters K. Methylglyoxal Mediates the Association Between 2—Hour Plasma Glucose and HbA1c With Inflammation: The Maastricht Study. J Clin Endocrinol Metab. 2025; 110: 2047-54.

[78] Reyaz A, Alam S, Chandra K, Kohli S, Agarwal S. Methylglyoxal and soluble RAGE in type 2 diabetes mellitus: Association with oxidative stress. J Diabetes Metab Disord. 2020; 19: 515—21.

[79] Ribeiro RT, Macedo MP, Raposo JF. HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions. Curr Diabetes Rev. 2016; 12: 14-9.

[80] Patury S, Miyata Y, Gestwicki JE. Pharmacological targeting of the Hsp70 chaperone. Curr Top Med Chem. 2009; 9: 1337-51.

[81] Duncan EJ, Cheetham ME, Chapple JP, van der Spuy J. The role of HSP70 and its co—chaperones in protein misfolding, aggregation and disease. Subcell Biochem. 2015; 78: 243-73.

[82] Pal R, Bhadada SK. AGEs accumulation with vascular complications, glycemic control and metabolic syndrome: A narrative review. Bone. 2023; 176: 116884.

[83] Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin North Am. 2013; 42: 697-719.

[84] Sirover MA. On the functional diversity of glyceraldehyde—3—phosphate dehydrogenase: biochemical mechanisms and regulatory control. Biochim Biophys Acta. 2011; 1810: 741-51.

[85] Beisswenger PJ, Howell SK, Smith K, Szwergold BS. Glyceraldehyde—3—phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim Biophys Acta. 2003; 1637: 98-106.

[86] Nakajima H, Amano W, Fujita A, Fukuhara A, Azuma YT, Hata F, et al. The active site cysteine of the proapoptotic protein glyceraldehyde—3—phosphate dehydrogenase is essential in oxidative stress—induced aggregation and cell death. J Biol Chem. 2007; 282: 26562—74.

[87] Talwar D, Miller CG, Grossmann J, Szyrwiel L, Schwecke T, Demichev V, et al. The GAPDH redox switch safeguards reductive capacity and enables survival of stressed tumour cells. Nat Metab. 2023; 5: 660-76.

[88] de Bari L, Scirè A, Minnelli C, Cianfruglia L, Kalapos MP, Armeni T. Interplay among Oxidative Stress, Methylglyoxal Pathway and S—Glutathionylation. Antioxidants (Basel). 2020; 10: 19.

[89] Chauhan AS, Kumar M, Chaudhary S, Dhiman A, Patidar A, Jakhar P, et al. Trafficking of a multifunctional protein by endosomal microautophagy: linking two independent unconventional secretory pathways. FASEB J. 2019; 33: 5626-40.

[90] Mikeladze MA, Dutysheva EA, Kartsev VG, Margulis BA, Guzhova IV, Lazarev VF. Disruption of the Complex between GAPDH and Hsp70 Sensitizes C6 Glioblastoma Cells to Hypoxic Stress. Int J Mol Sci. 2021; 22: 1520.

[91] De Maio A, Santoro MG, Tanguay RM, Hightower LE. Ferruccio Ritossa’s scientific legacy 50 years after his discovery of the heat shock response: a new view of biology, a new society, and a new journal. Cell Stress Chaperones. 2012; 17: 139-43.

[92] Ambrose AJ, Chapman E. Function, Therapeutic Potential, and Inhibition of Hsp70 Chaperones. J Med Chem. 2021; 64: 7060-82.

[93] Borges TJ, Wieten L, van Herwijnen MJ, Broere F, van der Zee R, Bonorino C, et al. The anti—inflammatory mechanisms of Hsp70. Front Immunol. 2012; 3: 95.

[94] Belenichev IF, Aliyeva OG, Popazova OO, Bukhtiyarova NV. Involvement of heat shock proteins HSP70 in the mechanisms of endogenous neuroprotection: the prospect of using HSP70 modulators. Front Cell Neurosci. 2023; 17: 1131683.

[95] Zhang B, Qi R. The dual—function of HSP70 in immune response and tumor immunity: from molecular regulation to therapeutic innovations. Front Immunol. 2025; 16: 1587414.

[96] Hu B, Liu G, Zhao K, Zhang G. Diversity of extracellular HSP70 in cancer: advancing from a molecular biomarker to a novel therapeutic target. Front Oncol. 2024; 14: 1388999.

[97] Komarova EY, Suezov RV, Nikotina AD, Aksenov ND, Garaeva LA, Shtam TA, et al. Hsp70—containing extracellular vesicles are capable of activating of adaptive immunity in models of mouse melanoma and colon carcinoma. Sci Rep. 2021; 11: 21314.

[98] Ferretti GDS, Quarti J, Dos Santos G, Rangel LP, Silva JL. Anticancer Therapeutic Strategies Targeting p53 Aggregation. Int J Mol Sci. 2022; 23: 11023.

[99] Singh MK, Han S, Ju S, Ranbhise JS, Ha J, Yeo SG, et al. Hsp70: A Multifunctional Chaperone in Maintaining Proteostasis and Its Implications in Human Disease. Cells. 2025; 14: 509.

[100] Sojka DR, Abramowicz A, Adamiec—Organisciok M, Karnas E, Mielańczyk Ł, Kania D, et al. Heat shock protein A2 is a novel extracellular vesicle—associated protein. Sci Rep. 2023; 13: 4734.

[101] De Maio A. Extracellular heat shock proteins, cellular export vesicles, and the Stress Observation System: a form of communication during injury, infection, and cell damage. It is never known how far a controversial finding will go! Dedicated to Ferruccio Ritossa. Cell Stress Chaperones. 2011; 16: 235-49.

[102] De Maio A. Extracellular Hsp70: export and function. Curr Protein Pept Sci. 2014; 15: 225-31.

[103] Robinson MB, Taylor AR, Gifondorwa DJ, Tytell M, Milligan CE. Exogenous Hsc70, but not thermal preconditioning, confers protection to motoneurons subjected to oxidative stress. Dev Neurobiol. 2008; 68: 1-17.

[104] Gifondorwa DJ, Jimenz—Moreno R, Hayes CD, Rouhani H, Robinson MB, Strupe JL, et al. Administration of Recombinant Heat Shock Protein 70 Delays Peripheral Muscle Denervation in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Neurol Res Int. 2012; 2012: 170426.

[105] Zhan X, Ander BP, Liao IH, Hansen JE, Kim C, Clements D, et al. Recombinant Fv—Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats. Stroke. 2010; 41: 538-43.

[106] Shevtsov MA, Nikolaev BP, Yakovleva LY, Dobrodumov AV, Dayneko AS, Shmonin AA, et al. Neurotherapeutic activity of the recombinant heat shock protein Hsp70 in a model of focal cerebral ischemia in rats. Drug Des Devel Ther. 2014; 8: 639—50.

[107] Cunningham TJ, Greenstein J, Yao L. Uncompetitive Phospholipase A2 Inhibition by CHEC Sequences Including Oral Treatment of Experimental Autoimmune Myeloencephalitis. Open Enzyme Inhib J. 2009; 2: 1-7.

[108] Takemoto S, Nishikawa M, Takakura Y. Pharmacokinetic and tissue distribution mechanism of mouse recombinant heat shock protein 70 in mice. Pharm Res. 2005; 22: 419-26.

[109] Evgen’ev MB, Onikienko SB, Chuvakova LN, Garbuz DG, Zatsepina OG. The Role of Hsp70 in Adaptation to Adverse Conditions and Its Possible Medical Application. Front Biosci (Landmark Ed). 2023; 28: 25.

[110] Kavanagh K, Flynn DM, Jenkins KA, Zhang L, Wagner JD. Restoring HSP70 deficiencies improves glucose tolerance in diabetic monkeys. Am J Physiol Endocrinol Metab. 2011; 300: E894-901.

[111] Mirioglu S, Uludag O, Hurdogan O, Kumru G, Berke I, Doumas SA, et al. AA Amyloidosis: A Contemporary View. Curr Rheumatol Rep. 2024; 26: 248-59.

[112] Liu W, Xia S, Yao F, Huo J, Qian J, Liu X, et al. Deactivation of the Unfolded Protein Response Aggravated Renal AA Amyloidosis in HSF1 Deficiency Mice. Mol Cell Biol. 2024; 44: 165-77.

[113] Whitcomb EA, Chiu C, Taylor A. Dietary glycemia as a determinant of health and longevity. Mol Aspects Med. 2015; 46: 14-20.

[114] Taylor A. Mechanistically linking age—related diseases and dietary carbohydrate via autophagy and the ubiquitin proteolytic systems. Autophagy. 2012; 8: 1404-6.

[115] Tower J. Heat shock proteins and Drosophila aging. Exp Gerontol. 2011; 46: 355-62.

[116] Calderwood SK, Murshid A, Prince T. The shock of aging: molecular chaperones and the heat shock response in longevity and aging——a mini—review. Gerontology. 2009; 55: 550—8.

[117] Dutta N, Garcia G, Higuchi—Sanabria R. Hijacking Cellular Stress Responses to Promote Lifespan. Front Aging. 2022; 3: 860404.

[118] Lithgow GJ, White TM, Melov S, Johnson TE. Thermotolerance and extended life—span conferred by single—gene mutations and induced by thermal stress. Proc Natl Acad Sci U S A. 1995; 92: 7540—4.